GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemo ... Subscribe now to see this Premium News article from Alliance News ...

GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in the RUBY trial.

GSK’s PD-1 inhibitor Jemperli has been cleared for use by the NHS as a first-line treatment for a specific type of endometrial cancer, making it an option for around 580 women across England ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

Used to treat advanced or recurrent endometrial cancer, Jemperli Dostarlimab, presents an opportunity to enhance the immune response against cancer cells when combined with chemotherapy.

Used to treat advanced or recurrent endometrial cancer, Jemperli Dostarlimab, presents an opportunity to enhance the immune response against cancer cells when combined with chemotherapy. Get Your Free ...

Also in Europe, officials have endorsed GSK's Jemperli to treat all adult patients with primary advanced or recurrent endometrial cancer, including those with mismatch repair proficient (MMRp ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...